Viking Therapeutics Inc (NASDAQ:VKTX) Sellers Decreased By 0.3% Their Shorts

June 27, 2018 - By Joshua Cleveland

Viking Therapeutics, Inc. (NASDAQ:VKTX) Corporate Logo

Viking Therapeutics Inc (NASDAQ:VKTX) noted a decrease of 0.3% in short interest. In June was announced VKTX’s total 2.91 million short interest by FINRA. The 2.92M previous shares are down with 0.3%. Viking Therapeutics Inc (NASDAQ:VKTX) has 892,100 shares average volume. It’ll cost 3 days for VKTX to restore its previous position. Viking Therapeutics Inc float short is 15.78%.

Ticker’s shares touched $10.35 during the last trading session after 0.58% change.Viking Therapeutics, Inc. has volume of 1.30M shares. Since June 27, 2017 VKTX has risen 320.16% and is uptrending. VKTX outperformed by 307.59% the S&P500.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders.The firm is worth $616.43 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery.Last it reported negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

In total 4 analysts cover Viking Therapeutics (NASDAQ:VKTX). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. (NASDAQ:VKTX) has 100% bullish analysts. 5 are the (NASDAQ:VKTX)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Thursday, March 8 the rating was maintained by Roth Capital with “Buy”. The stock rating was maintained by Maxim Group with “Buy” on Friday, June 1. On Monday, March 26 the firm has “Buy” rating by H.C. Wainwright given. On Friday, June 1 H.C. Wainwright maintained the shares of VKTX in report with “Buy” rating.

For more Viking Therapeutics, Inc. (NASDAQ:VKTX) news released recently go to: Seekingalpha.com, Fool.com, Fool.com, Seekingalpha.com or Fool.com. The titles are as follows: “Viking Therapeutics: Hallmark Moment” released on June 13, 2018, “3 Growth Stocks at Deep-Value Prices” on June 15, 2018, “Viking Therapeutics, Buy the Dip?” with a publish date: June 26, 2018, “Viking Therapeutics: Sell The Pop On The Sympathy Play” and the last “Why Viking Therapeutics Stock Is On Fire Today” with publication date: May 31, 2018.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: